Alzheimer's Disease (AD) v frontotemporal dementia (FTD)
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Alzheimer's Disease (AD) v frontotemporal dementia (FTD). Younger onset age, Higher levels of educational attainment. Fully referenced neurology checklist.
Clinical features more suggestive of FTD
- Younger onset age
- Higher levels of educational attainment
- Better mini mental state examination (MMSE) scores
- Better memory in the early stages
- Worse executive and language functions
- Worse verbal scores
- A higher frequency of criminal behaviour
Cerebrospinal fluid (CSF) analysis
Locked: subscribe to see this section.
Magnetic resonance imaging (MRI) brain
Locked: subscribe to see this section.
Positron emission tomography (PET) scan
Locked: subscribe to see this section.
References
- Hutchinson AD, Mathias JL. Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. JNNP 2007; 78:917-928.
- Haußmann R, Krug C, Noppes F, Brandt M, Lange J, Donix M. Criminal behavior in frontotemporal dementia and Alzheimer's disease. Nervenarzt 2022; 93:59-67.
- Liljegren M, Naasan G, Temlett J, et al. Criminal behavior in frontotemporal dementia and Alzheimer disease. JAMA Neurol 2015; 72:295-300.
- de Souza LC, Lamari F, Belliard S, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. JNNP 2011; 82:240-246.
- de Jong D, Jansen RWMM, Pijnenburg YAL, et al. CSF neurofilament proteins in the differential diagnosis of dementia. JNNP 2007; 78:936-938.
- And 2 more. Subscribe to see the full list
Related checklists
- Alzheimer’s disease (AD): risk factors
- Alzheimer’s disease (AD): protective factors
- Alzheimer’s disease (AD): clinical features
- Alzheimer’s disease (AD): investigations
- Alzheimer’s disease (AD): emerging investigations
- Alzheimer’s disease (AD): preventative measures
- Alzheimer’s disease (AD): non-drug management
- Alzheimer’s disease (AD): conventional drug treatments
- Alzheimer’s disease (AD): lecanemab treatment
- Alzheimer’s disease (AD): investigational treatments
- Alzheimer’s disease: driving and safety issues